ahlam1399
08-01-2016, 06:47 PM
Biogen pays Ionis $75 million to develop muscle drug after trial success
(Reuters) - Biogen Inc said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement in symptoms.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=2kAYfFXRxgc:lWFzD1-4rO8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=2kAYfFXRxgc:lWFzD1-4rO8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/2kAYfFXRxgc
(Reuters) - Biogen Inc said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement in symptoms.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=2kAYfFXRxgc:lWFzD1-4rO8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=2kAYfFXRxgc:lWFzD1-4rO8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=2kAYfFXRxgc:lWFzD1-4rO8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/2kAYfFXRxgc